A Phase II, Non-Randomized, Multicenter Study to Evaluate the Safety and Efficacy of Pazopanib (GW786034) as Pre-Surgical Therapy in Treatment-Naive Subjects With Stage IA or IB, Resectable Non Small Cell Lung Cancer (NSCLC).
Phase of Trial: Phase II
Latest Information Update: 03 Jun 2015
At a glance
- Drugs Pazopanib (Primary)
- Indications Non-small cell lung cancer
- Focus Biomarker; Therapeutic Use
- 10 Jun 2017 Biomarkers information updated
- 11 Aug 2009 Actual patient number (35) added as reported by ClinicalTrials.gov.
- 15 Sep 2008 Data presented at ESMO 2008 according to GlaxoSmithKline media release.